NCT02503839View on ClinicalTrials.gov

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2019

Study Completion Date

March 23, 2020

Conditions
Tuberculosis
Interventions
DRUG

etoricoxib

cyclooxygenase-2 inhibitor. Anti-inflammatory

BIOLOGICAL

H56:IC31

Therapeutic and prophylactic TB vaccine

Trial Locations (2)

5020

Haukeland University Hospital, Bergen

0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

University of Oslo

OTHER

collaborator

Statens Serum Institut

OTHER

collaborator

Haukeland University Hospital

OTHER

lead

Anne Margarita Dyrhol Riise

OTHER

NCT02503839 - Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic | Biotech Hunter | Biotech Hunter